Jason C. O'Connor

Dr. Jason C. O'Connor

Department of Pharmacology, UT Health San Antonio and South Texas Veterans Health Care System, San Antonio, TX, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Hormones and Behavior
Verified
Journal Article
Closed access
ASAlexander Salazar
Alexander Salazar
BGBryan L. Gonzalez-Rivera
Bryan L. Gonzalez-Rivera
LRLaney Redus
Laney Redus
JPJennifer M. Parrott
Jennifer M. Parrott
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor

1 January 2010 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
ACAngela W Corona
Angela W Corona
YHYan Huang
Yan Huang
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor
RDRobert Dantzer
Robert Dantzer
Keith W KelleyKeith W Kelley
Keith W Kelley
JGJonathan P. Godbout
Jonathan P. Godbout
Interactions between fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) regulate microglial activation in the CNS. Recent findings indicate that age-associated impairments in CX3CL1 and CX3CR1 are directly associated with exaggerated microglial activation and an impaired recovery from sickness behavior after peripheral injection of lipopolysaccharide (LPS). Therefore, the purpose of this study was to determine the extent to which an acute LPS injection causes amplified and prolonged microglial activation and behavioral deficits in CX3CR1-deficient mice (CX3CR1-/-).

19 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
Mustafa MithaiwalaMustafa Mithaiwala
Mustafa Mithaiwala
DCDanielle Santana Coelho
Danielle Santana Coelho
GPGrace A. Porter
Grace A. Porter
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor
Diseases of the central nervous system (CNS) remain a significant health, social and economic problem around the globe. The development of therapeutic strategies for CNS conditions has suffered due to a poor understanding of the underlying pathologies that manifest them. Understanding common etiological origins at the cellular and molecular level is essential to enhance the development of efficacious and targeted treatment options. Over the years, neuroinflammation has been posited as a common link between multiple neurological, neurodegenerative and neuropsychiatric disorders. Processes that precipitate neuroinflammatory conditions including genetics, infections, physical injury and psychosocial factors, like stress and trauma, closely link dysregulation in kynurenine pathway (KP) of tryptophan metabolism as a possible pathophysiological factor that ‘fuel the fire’ in CNS diseases. In this study, we aim to review emerging evidence that provide mechanistic insights between different CNS disorders, neuroinflammation and the KP. We provide a thorough overview of the different branches of the KP pertinent to CNS disease pathology that have therapeutic implications for the development of selected and efficacious treatment strategies.

19 January 2022 in World Journal of Psychiatry
Verified
Journal Article
Open access
GPGrace A Porter
Grace A Porter
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor
Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?

18 October 2016 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JPJ M Parrott
J M Parrott
LRL Redus
L Redus
DCDanielle Santana Coelho
Danielle Santana Coelho
JMJ Morales
J Morales
XGX Gao
X Gao
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor
The kynurenine pathway of tryptophan metabolism has an important role in mediating the behavioral effects of inflammation, which has implications in understanding neuropsychiatric comorbidity and for the development of novel therapies. Inhibition of the rate-limiting enzyme, indoleamine 2,3-dioxygenase (IDO), prevents the development of many of these inflammation-induced preclinical behaviors. However, dysregulation in the balance of downstream metabolism, where neuroactive kynurenines are generated, is hypothesized to be a functionally important pathogenic feature of inflammation-induced depression. Here we utilized two novel transgenic mouse strains to directly test the hypothesis that neurotoxic kynurenine metabolism causes depressive-like behavior following peripheral immune activation. Wild-type (WT) or kynurenine 3-monooxygenase (KMO)-deficient (KMO−/−) mice were administered either lipopolysaccharide (LPS, 0.5 mg kg−1) or saline intraperitoneally. Depressive-like behavior was measured across multiple domains 24 h after immune challenge. LPS precipitated a robust depressive-like phenotype, but KMO−/−mice were specifically protected from LPS-induced immobility in the tail suspension test (TST) and reduced spontaneous alternations in the Y-maze. Direct administration of 3-hydroxykynurenine, the metabolic product of KMO, caused a dose-dependent increase in depressive-like behaviors. Mice with targeted deletion of 3-hydroxyanthranilic acid dioxygenase (HAAO), the enzyme that generates quinolinic acid, were similarly challenged with LPS. Similar to KMO−/−mice, LPS failed to increase immobility during the TST. Whereas kynurenine metabolism was generally increased in behaviorally salient brain regions, a distinct shift toward KMO-dependent kynurenine metabolism occurred in the dorsal hippocampus in response to LPS. Together, these results demonstrate that KMO is a pivotal mediator of hippocampal-dependent depressive-like behaviors induced by peripheral LPS challenge.

1 August 2018 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
AGAllison M. Garrison
Allison M. Garrison
JPJennifer M. Parrott
Jennifer M. Parrott
ATArnulfo Tuñon
Arnulfo Tuñon
JDJennifer Delgado
Jennifer Delgado
LRLaney Redus
Laney Redus
Jason C. O'ConnorJason C. O'Connor
Jason C. O'Connor